PE20091365A1 - Anticuerpos modificadores de enfermedades cancerosas - Google Patents

Anticuerpos modificadores de enfermedades cancerosas

Info

Publication number
PE20091365A1
PE20091365A1 PE2009000114A PE2009000114A PE20091365A1 PE 20091365 A1 PE20091365 A1 PE 20091365A1 PE 2009000114 A PE2009000114 A PE 2009000114A PE 2009000114 A PE2009000114 A PE 2009000114A PE 20091365 A1 PE20091365 A1 PE 20091365A1
Authority
PE
Peru
Prior art keywords
cancer disease
disease modifying
modifying antibodies
cytotoxic
refers
Prior art date
Application number
PE2009000114A
Other languages
English (en)
Inventor
David S F Young
Helen P Findlay
Susan E Hahn
Lisa M Cechetto
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20091365A1 publication Critical patent/PE20091365A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL, QUIMERICO O HUMANIZADO PRODUCIDO POR EL HIBRIDOMA DEPOSITADO CON EL IDAC COMO NUMERO DE ACCESO 181207-01, QUE SE UNE ESPECIFICAMENTE A UN EPITOPE EXPRESADO POR UN TUMOR HUMANO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO ANTICUERPO CONJUGADO CON MITADES CITOTOXICAS, ENZIMAS, COMPUESTOS RADIACTIVOS, ENTRE OTROS. DICHOS ANTICUERPOS SON CITOTOXICOS Y CITOSTASICOS SIENDO UTILES PARA EL TRATAMIENTO DE CANCER Y METASTASIS TUMORAL
PE2009000114A 2008-01-28 2009-01-28 Anticuerpos modificadores de enfermedades cancerosas PE20091365A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2405608P 2008-01-28 2008-01-28

Publications (1)

Publication Number Publication Date
PE20091365A1 true PE20091365A1 (es) 2009-09-23

Family

ID=40899465

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000114A PE20091365A1 (es) 2008-01-28 2009-01-28 Anticuerpos modificadores de enfermedades cancerosas

Country Status (9)

Country Link
US (1) US20090191197A1 (es)
EP (1) EP2238171A4 (es)
JP (1) JP2011511767A (es)
AR (1) AR070280A1 (es)
CA (1) CA2712535A1 (es)
CL (1) CL2009000175A1 (es)
PE (1) PE20091365A1 (es)
TW (1) TW200938635A (es)
WO (1) WO2009117804A1 (es)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
NZ222509A (en) * 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5171655A (en) * 1989-08-03 1992-12-15 Fuji Photo Film Co., Ltd. Photohardenable light-sensitive composition
EP0539970B1 (en) * 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
IL105008A0 (en) * 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
DE69432926T2 (de) * 1993-02-05 2004-05-13 Epigen, Inc., Wellesley Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
DE69518919T2 (de) * 1994-06-24 2001-03-29 Vladimir P Torchilin Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
AU2002226211A1 (en) * 2001-12-21 2003-07-15 Arius Research, Inc. Individualized anti-cancer antibodies
WO2007095745A1 (en) * 2006-02-24 2007-08-30 Arius Research Inc. Cancerous disease modifying antibody 141205-02
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US20080213170A1 (en) * 2007-01-23 2008-09-04 Young David S F Cancerous Disease Modifying Antibodies
US20080206133A1 (en) * 2007-01-23 2008-08-28 Young David S F Cancerous Disease Modifying Antibodies
WO2009009882A1 (en) * 2007-07-16 2009-01-22 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
CN101743256A (zh) * 2007-07-16 2010-06-16 霍夫曼-拉罗奇有限公司 抗癌细胞毒性单克隆抗体

Also Published As

Publication number Publication date
AR070280A1 (es) 2010-03-25
CL2009000175A1 (es) 2010-02-12
EP2238171A1 (en) 2010-10-13
TW200938635A (en) 2009-09-16
JP2011511767A (ja) 2011-04-14
EP2238171A4 (en) 2011-10-19
US20090191197A1 (en) 2009-07-30
WO2009117804A1 (en) 2009-10-01
CA2712535A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
CO2017005845A2 (es) Anticuerpos monoclonales aislados contra cd73
CO6140062A2 (es) Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas
BR112019005697A2 (pt) anticorpos anti-muc16-cd3 biespecíficos e conjugados de fármaco e anti-muc16
AR080513A1 (es) Moleculas de union cd37 y sus inmunoconjugados
PE20141017A1 (es) Anticuerpos del cea
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
AR091703A1 (es) Anticuerpos e inmunoconjugados que comprenden anticuerpos anti-cd22
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
DOP2013000219A (es) Anticuerpos imitadores de receptores de celulas t especificos para peptido wt1 unido a hla-a2
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
AR091605A1 (es) Proteinas de union anti-mesotelina
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
CO6241160A2 (es) Anticuerpos anti-cd44 quiméricos y humanizados que median la citotoxicidad de celulas de cancer
CO6382188A2 (es) Anticuerpos monoclonales que se unen al hgm-csf y composiciones medicas que los comprenden
AR091702A1 (es) Anticuerpos anti-cd79b e inmunoconjugados
RU2014103784A (ru) Антитело, блокирующее agr2, и его применение
ECSP12012138A (es) Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello
PE20081553A1 (es) Composicion farmaceutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide
CO6331345A2 (es) Composiciones y métodos que proporcionan una línea celular de hibridoma depositada como no. de acceso atcc pta-9387 y un anticuerpo producido por esta línea celular de hibridoma
AR077972A1 (es) Anticuerpos contra cdcp1 destinados al tratamiento del cancer
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
CO2018004930A2 (es) Moléculas de unión específicas para asct2

Legal Events

Date Code Title Description
FD Application declared void or lapsed